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TABLE 
NS (1) SS NS (2) SS NS (3) SS 
No Antibiotics 13.1% 9.8% 0.0% 0.0% -13.1 -9.8 
Oral Synthetic Penicillin 
Oral Cephalosporin (CE) 
Parenteral Cephalosporin 
P-Lactam. Resist. Oral CE 
Quinolone 
Macrolide 
10.7% 11.8% 5.5% 7.5% -5.2 -4.3 
48% 3.9% 6.3% 2.9% 1.5 -1.0 
4.8% 9.8% 25.0% 41.4% 20.2 31.6 
14.3% 3.9% 10.2% 18% -4.1 1.6 
23.8% 49.0% 31.2% 41.4% 7.4 -7.6 
28.6% 11.8% 35.8% 5.0% -6.9 -6.8 
8/99 we performed 704 examinations (exams) on 390 COPD patients (age 66.4? 3 1, M 275). 180 exams of patients with FEVl 
<50%pred were classified as severe (SS); the remaining 524 exams were classified as NS. Among NS exams we identified 84 
AECB (age 64.3?21, AcI 29.8%, AcII 42.9%, AcIII 27.4%) whereas 51 AECB were recorded among SS exams (age 
67.4+37,AcI 42.9%, AcII 43.1%, AcIII 11.8%). Decisions regarding whether and how to treat were left to visiting physicians. 
The table shows for each ATR and for each severity group: (1) the % of AECB, (2) the % of total costs attributable to ATR 
and (3) the difference between the two above percentages. In deciding whether and how to treat AECB, adherence to 
international guidelines was not complete. The overall costs of ATR was 5,861 US$. ATR costs for AECB in COPD-SS were 
60 US$, whereas for NS patients were 32 US$. The greater cost for SS AECB is mainly attributable to use of the parenteral 
antibiotics. 
8. AECB in an out-patient pulmonary setting and smoking habit 
S. DAMATO, R. RACCANELLI, C. RAMPOLDI, T. CAMNASIO, L. CHIESA, V. FRIGO, 
G. NEGRETTO AND F. RODI 
Pulmonary Rehabilitation Unit (Seregno), University of Milano-Bicocca, Italy 
In 555 COPD patients we performed 970 examinations (exams) over a one year period. 186 exams (age 65.5+21, males 125) 
have been classified as exacerbations (AECB), according to Anthonisen: 41% in ex-smokers (EX), 29% in non smokers (N) 
and 30% in smokers (S). We have subdivided the AECB exams also in relation to seasons (autumn-winter=AW, spring- 
summer=SS), as shown in the table. 
TABLE 
EX N S 
AW 51.3% 57.4% 64.2% 
ss 48.7% 42.6% 35.8% 
Actual or former smoking habit is related with higher prevalence of AECB. Only in ex smokers is the prevalence of EACB 
almost the same during the year. 
9. Lower respiratory infections: observational study in Genoa 
A. DE MARIA, M. BERARDI, L. FERRERA, I? ORSI, I. STARA AND G. W. CANONICA 
Allergy and Respiratory Diseases, Dept. of Internal Medicine, University of Genoa, Italy 
Background: lower respiratory tract infections (LRTI) are responsible for significant morbility, mortality and costs in all 
developed countries. To provide improved care for patients with LRTI, international and local guidelines for clinical and 
antibiotic management have been issued over the years. 
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Population and methods: we analysed 110 episodes of CAP or AECB in 107 pts in our unit from l/Dee/98 to 30/O&99; we 
evaluated antibiotic treatment before and during hospitalization, sputum isolates and serology, mean hospital stay. 
Results: CAP and AECB represented respectively 28% and 61% of the episodes; mean age was 63221~ (16-92y) and 70&9y 
(43-93y) in the 2nd group. Mean hospitalization was 20? 11 d (845d) for CAP and 19+ 12 d (3-75d) for AECB episodes. 71% 
of patients with CAP and 45% of those with AECB had received antibiotic treatment in the 3 days before admission. 43% of 
the patients with CAP received more than one drug; drugs including penicillins (P), cephalosporins (C), fluoroquinolones 
(FQ), macrolides (M). FQ were most frequently used for AECB, followed by C,M,P In 42% of CAP, no germs were isolated 
and in 29% of the cases multiple agents were identified. Similarly no pathogen was identified in 53% of AECB. 
Conclusions: an increased hospital stay in both CAP and AECB episodes was observed compared to mean national values, 
possibly related to patients’ demographics. Relevant differences in ethiology of CAP and AECB were observed compared to 
available reports at other sites, with no recorded case of Pen R S. Pneumoniae. These data further confirm that local 
guidelines and hospital formularies should take into account both clinical and microbiological surveys. 
10. Clinical efficacy and safety of clarithromycin in the initial treatment of community 
acquired pneumonia 
J. DERNIC, A. JERMAN* AND J. DRINOVEC* 
Outpatient Clinic for Pulmonary Diseases, Koper; *Krka, d.d., Novo mesto, Slovenia 
Aim: to evaluate efficacy and safety of clarithromycin in the initial treatment of community-acquired pneumonia (CAP) in a 
prospective, noncomparative, multicentre clinical trial. 
Patients and methods: 87 outpatients with symptoms and radiologically confirmed pneumonia were included. We evaluated 
clinical symptoms at the beginning of the treatment, after three days and after the end of the treatment. Chest x-ray and 
laboratory findings including C-reactive protein (CRP) were evaluated at the beginning and not later than 9 days after the end 
of the treatment. Patients received 500 mg of clarithromycin twice daily. 
Results: Duration of treatment was 5 to 14 days (mean 1223 days). Complete radiological resolution was achieved in 72 
patients (85%). Chest pain was present in 67% before and 6% after the treatment, productive cough in 54% vs. 13%, non- 
productive cough in 46% vs. 17%, purulent sputum in 22% vs. O%, muco-purulent sputum in 28% vs. 6%, dyspnea in 54% vs. 
1 l%, chills in 55% vs. l%, pathological physical chest examination in 86% vs. 5%. Mean CRP was 53.0239.9 (SD) mg/l before 
and 11.3? 14.9 (SD) mg/l after the treatment. 97% of patients (84187) were successfully treated (cure or improvement). In 2 
out of 3 failures patients did not complete the treatment due to adverse reactions. 16% (14/87) of all patients experienced 
adverse reactions; most common were transient gastrointestinal symptoms. 
Conclusions: Initial treatment with clarithromycin was highly effective in mild to moderate CAP in adults, and was associated 
with an acceptable incidence of adverse reactions. 
11. Outcome factors in acute exacerbation of chronic obstructive lung disease 
N. A. DEWAN, S. RAFIQUE, B. KANWAR, H. SATPATHY, K. RYSCHON, G. S. TILLOTSON*, 
M.S. NIEDERMAN~ 
Creighton University, Omaha, NE; “Bayer Pharmaceuticals, Inc., New Haven ClJ 
t Winthrop University Hospital, Mineola, NX US. A. 
Objective. The purpose of this study was to determine the effect of age, severity of lung disease, severity and frequency of 
exacerbation, steroid use, choice of an antibiotic and the presence of comorbidity on the outcome of treatment for an acute 
exacerbation of chronic obstructive lung disease (COPD). 
Methods. A retrospective chart analysis was conducted in 107 outpatients with COPD who were treated with an antibiotic for 
an acute exacerbation of COPD over 24 months. Severity of an acute exacerbation was defined using Anthonisen’s criteria of 
increased dyspnea, increased sputum volume and increased sputum purulence. Severity of lung disease was stratified based on 
FEVi% predicted using ATS guidelines (Stage I - FEVl 50%; Stage II - FEVi 35% to 49%; Stage III ~ FEVi ~35%). 
Treatment outcome was judged successful when the patient had no return visit in four weeks for a respiratory problem. Failure 
was defined as a return visit in four weeks for persistent respiratory symptoms that required a change of an antibiotic. 
Results. One-hundred and seven patients with COPD (mean age&SD 66.9k9.5 years) experienced 232 exacerbations over 24 
months. First-line antibiotics (trimethoprim-sulfamethoxazole, ampicillinlamoxicillin and erythromycin) were used to treat 
78% of all exacerbations. Treatment failure was noted in 12.1% of first exacerbations and 14.7% of all exacerbations, with 
more than half the failures requiring hospitalization Host factors that were independently associated with treatment failure 
